Career Center




Industry Insights

KPMG: Leadership Thought on Pharma in China

Date:   Wednesday, December 14, 2011
Time:   12:00 Noon - 1:00 pm
Sponsor:   School of Medicine Career Center
Event details:  

Register HERE to attend

KPMG Presents
China’s Pharmaceutical Industry – Poised for the Giant Leap

Wednesday, December 14, 2011
12:00-1:15 PM
Stanford School of Medicine – LKSC 101

Presented by:
David Blumberg, Advisory Partner in Charge of U.S. Pharmaceuticals & Life Sciences
Brian Wilson, Advisory Director, Global China Practice

Sponsored by:
School of Medicine Career Center
RSVP Required: Send email to



China is focused on transforming its economy from one that has been focused on double-digit GDP growth, exports, and serving as a low-cost manufacturing and labor base for the past three decades to one focused on sustainable growth, domestic consumption, and increasing its place in the value chain through technological superiority and indigenous innovation. Indeed, China stands at the cusp of a modern society, increasingly affluent and with a growing urban population demanding better services and quality of life. The government is also aware of the need to undertake a systemic overhaul of social, economic and financial structures for a more balanced society. Key components of this new agenda are an efficient pharmaceutical value chain and cultivating and leveraging indigenous innovation.

In 2009, China launched an aggressive healthcare reform plan aimed at bringing all its citizens under basic medical coverage, modernizing health infrastructure and delivery, and overhauling the pharmaceutical industry. China’s 12th Five Year plan focuses on achieving this through continuous reform and policy incentives. Two main focus areas are the consolidation of the pharmaceutical distribution sector and biotechnology. China hopes to streamline and integrate its drug distribution and bring pharmaceutical production and sales closer together to reduce medicine prices; and biotechnology has been singled out as one of the seven ‘strategic emerging industries’. More investment in this biotech sector in particular can help resolve health problems associated with China’s rapidly ageing society, and we can expect the government to support innovative biotech products, high-end medical devices, and patented medicines.

In this session, you will hear from KPMG’s experts on the pharmaceutical and biotechnology sectors in China. They will discuss the China market place, the government’s ambitions, how its long-term strategic goals in the pharmaceutical and biotechnology sectors will impact companies operating globally, and the trends that are impacting and will continue to steer the development of these sectors in China.



David Blumberg, Advisory Partner in Charge of Global Pharmaceuticals & Life Sciences
David leads KPMG’s Global Pharmaceuticals and Life Sciences Advisory practice.   David has over 20 years of experience advising clients on a broad range of strategic, operational, information technology, and regulatory topics.  He has worked across the life sciences continuum for over 18 years with experience in large global pharmaceuticals, specialty pharmaceuticals, generic pharmaceuticals, biotech, medical device, medical products, and diagnostics.

Brian Wilson, Advisory Director, US-China Practice Leader for the Midwest
Brian is a Director with KPMG’s Advisory Services practice with more than 14 years of management advisory and business experience. He recently returned to KPMG US after spending 3 years with KPMG China where he led KPMG’s anti-bribery and corruption services for the Asia Pacific region while based in Shanghai. Brian worked closely with US and China partners in the Corporate Finance, Valuations, Transactions Services, International Tax, Supply Chain Management, Risk and Compliance, IT Advisory and Integration service lines to provide comprehensive solutions to clients to help them operate profitability and ethically in China and Hong Kong.
Brian is currently focused on assisting US and Chinese companies with cross-border transactions and activities including market entry and expansion, US regulatory compliance, cross-border investigations and litigation, and forensic technology services. Similar to when he was in China, he focuses on helping companies with finding comprehensive solutions to their US and China needs and is a member of our Global China Practice and Investigations Services Network.

KPMG International
KPMG is a global network of professional firms providing Audit, Tax, and Advisory services. We operate in 150 countries and have 138,000 people working in member firms around the world. The independent member firms of the KPMG network are affiliated with KPMG International, a Swiss cooperative. Each KPMG firm is a legally distinct and separate entity and describes itself as such.

KPMG in the U.S.
KPMG LLP, the audit, tax and advisory firm (, is the U.S. member firm of KPMG International Cooperative (“KPMG International”). KPMG International's member firms have 138,000 professionals, including more than 7,900 partners, in 150 countries.

Register HERE to attend

Footer Links: